DUX4 and precursor B-cell acute lymphoblastic leukemia: We developed a novel, customised analytical approach that identified 57 B-ALL patients with >10 spanning reads per billion (SRPB) between IGH and DUX4 (Fig. 5A, Supplementary Information, Supplementary Table 6).